title: [The value of radiotherapy in the treatment of aggressive and localised gastric lymphomas].
abstract: OBJECTIVE
  To evaluate the treatment results of localised aggressive gastric lymphomas with favourable prognosis using chemotherapy and radiotherapy.
  
  
  METHODS
  Between February 1993 and December 2004, nine patients with primary gastric high-grade lymphoma have been treated by the Lymphoma Committee of Sfax (Tunisia). The sex ratio was 1.5. The mean age was 44.9 years. Histological type was the large cell B lymphoma in 100% of the cases. Disease was stage I in eight cases and stage II in one case (Ann Arbor Classification). The treatment consisted in primary chemotherapy followed by radiotherapy of the stomach with or without regional nodes (40 Gy).
  
  
  RESULTS
  After treatment, all patients had complete remission. With a mean follow-up of 55.7 months, one patient was lost to follow-up; the other patients were alive with complete remission. No major acute toxicities or late effects were found. Overall survival was 100% at five years.
  
  
  CONCLUSIONS
  Chemotherapy associated with radiotherapy can be proposed to patients having localised and aggressive primary gastric lymphoma with favourable prognosis, since this treatment is well tolerated and provides satisfactory control of the disease.
authors.affiliation: Service de radiothérapie carcinologique, CHU Habib-Bourguiba, rue Majida-Bouleïla, 3029 Sfax, Tunisie. ben_salah_hanen@yahoo.fr
authors.forename: H
authors.initials: H
authors.lastname: Ben Salah
authors.forename: L
authors.initials: L
authors.lastname: Ghorbel
authors.forename: M S
authors.initials: MS
authors.lastname: Krichen
authors.forename: H
authors.initials: H
authors.lastname: Bellaaj
authors.forename: M
authors.initials: M
authors.lastname: Elloumi
authors.forename: M
authors.initials: M
authors.lastname: Frikha
authors.forename: J
authors.initials: J
authors.lastname: Daoud
mesh_terms: D000046:Academic Medical Centers; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D015251:Epirubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018579:Patient Selection; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction / Q000379:methods; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D015996:Survival Rate; D016896:Treatment Outcome; D014416:Tunisia / Q000453:epidemiology; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D015251:Epirubicin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone